THEO-260 NCT07211659 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1

Clinical phase

Recruiting

Recruitment status

18

Planned enrollment

2027-09-01

Primary-completion proxy

Executive view

NCT07211659 evaluates THEO-260 in Ovarian Cancer. The disclosed sponsor is Theolytics Ltd., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Safety and tolerability of THEO-260, assessed over Until Day 28 after first dose.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07211659 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Ovarian Cancer landscape. Drug & Asset MCP drug_fetch was queried for THEO-260, while Company & Deal Intelligence MCP organization_fetch was queried for Theolytics Ltd..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07211659	THEO-260	Phase 1 / Recruiting	Theolytics Ltd.	United States	Safety and tolerability of THEO-260 Until Day 28 after first dose	2027-09-01
NCT07278986	Pafolacianine	Early Phase 1 / Recruiting	Abramson Cancer Center	United States	Primary Endpoint 2 months after surgery	2027-10-01
NCT07262619	EIK-1005	Phase 1/2 / Recruiting	Eikon Therapeutics, Inc.	Singapore, United States, Portugal, Spain, New Zealand, South Korea, Austria, Belgium, Norway, Finland, Poland, Italy, Australia, Germany	Dose-Limiting Toxicity (DLT) - Part 1 21 Days	2029-03-01
NCT07227168	Pembrolizumab	Phase 1 / Recruiting	Sutro Biopharma, Inc.	United States	Part 1A: Number of participants with Dose-limiting Toxicities (DLTs) Up to Day 21	2027-12-01
NCT07216105	Trastuzumab	Phase 1 / Recruiting	Fate Therapeutics, Inc.	United States	Number of participants with dose limiting toxicities (DLTs) From Day 1 through Day 29 of Cycle 1( each cycle is 56 days)	2028-01-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07211659 is a Phase 1, recruiting study with 18 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Safety and tolerability of THEO-260” over “Until Day 28 after first dose.” The retrieved endpoint description is: Assessment of DLTs and AEs during treatment and follow-up using NCI CTCAE v5.0 or ASCO (for pneumonitis only) or ASTCT (for CRS only), plus Laboratory parameters and clinical safety assessments..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 18 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Ovarian Cancer. These records do not establish direct evidence for NCT07211659 unless the registration number matches.

Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium

Phase 2; n=27; ORR = 44 percentage of participants (90% Confidence Interval, 27.0 - 62.1) Source: https://clinicaltrials.gov/ct2/show/results/NCT03643510

A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhib…

Phase 1/2; n=97; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 62 Participants ; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 3 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05572684

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2; n=62; CBR = 27 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01797523

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

THEO-260 is indexed as Oncolytic virus with target not reported biology and a global stage of Phase 1/2. The asset profile lists Theolytics Ltd. as an originator or developer.

Theolytics Ltd. is indexed in United Kingdom with the website https://www.theolytics.com. Theolytics is a clinical stage biotechnology company developing next-generation viral therapies. The record lists 3 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether THEO-260 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07211659
Protocol source: https://clinicaltrials.gov/study/NCT07211659
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.

THEO-260 in Ovarian Cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Safety and tolerability of THEO-260 and 2027-09-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP